- Diagnostic Différentiel
- Essayez d'établir votre recherche sur un attribut à la fois, et soyez aussi spécifique que possible! Exemple : "toux chronique".
- Ne pas entrer les résultats multiples tels que "anémie, toux chronique, perte de poids, vomissant" tous en même temps.
- Après sélection de votre attribut, une liste de diagnostics possibles sera générée. Si la liste est trop longue, vous pourrez la réduire en écrivant des attribut additionnels.
- Ne pas écrire les valeurs telles que le "rythme cardiaque 110" ou le "sodium 125", mais plutôt "tachycardie" ou "hyponatrémie".
Drug Information for GLIPIZIDE TABLETS USPFor Oral UseRx only (Ivax Pharmaceuticals, Inc.): ADVERSE REACTIONS
- INDICATIONS AND USAGE
- ADVERSE REACTIONS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- Diseases/Conditions Related to GLIPIZIDE TABLETS USPFor Oral UseRx only (Ivax Pharmaceuticals, Inc.)
- Liens externes liés à GLIPIZIDE TABLETS USPFor Oral UseRx only (Ivax Pharmaceuticals, Inc.)
In U.S. and foreign controlled studies, the frequency of serious adverse reactions reported was very low. Of 702 patients, 11.8% reported adverse reactions and in only 1.5% was glipizide discontinued.
Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections.
Gastrointestinal: Gastrointestinal disturbances are the most common reactions. Gastrointestinal complaints were reported with the following approximate incidence: nausea and diarrhea, one in seventy; constipation and gastralgia, one in one hundred. They appear to be dose-related and may disappear on division or reduction of dosage. Cholestatic jaundice may occur rarely with sulfonylureas: Glipizide should be discontinued if this occurs.
Dermatologic: Allergic skin reactions including erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, and eczema have been reported in about one in seventy patients. These may be transient and may disappear despite continued use of glipizide; if skin reactions persist, the drug should be discontinued. Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.
Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas.
Metabolic: Hepatic porphyria and disulfiram-like reactions have been reported with sulfonylureas. In the mouse, glipizide pretreatment did not cause an accumulation of acetaldehyde after ethanol administration. Clinical experience to date has shown that glipizide has an extremely low incidence of disulfiram-like alcohol reactions.
Endocrine Reactions: Cases of hyponatremia and the syndrome of inappropriate antidiuretic hormone (SIADH) secretion have been reported with this and other sulfonylureas.
Miscellaneous: Dizziness, drowsiness, and headache have each been reported in about one in fifty patients treated with glipizide. They are usually transient and seldom require discontinuance of therapy.
Laboratory Tests: The pattern of laboratory test abnormalities observed with glipizide was similar to that for other sulfonylureas. Occasional mild to moderate elevations of SGOT, LDH, alkaline phosphatase, BUN and creatinine were noted. One case of jaundice was reported. The relationship of these abnormalities to glipizide is uncertain, and they have rarely been associated with clinical symptoms.
- Drug Information Provided by National Library of Medicine (NLM).